Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway has recently reduced its stake in DaVita (DVA, Financial), a leading provider of kidney dialysis services in the United States. According to a filing with the U.S. Securities and Exchange Commission (SEC), Berkshire sold a total of 750,000 shares between February 14 and February 19, generating approximately $116 million.
This move follows a previous sale on February 11, where Berkshire sold about 203,000 shares at $156.011 per share, cashing in $31.69 million. After the recent transactions, Berkshire's holdings in DaVita have decreased to 35.14 million shares, representing a 43.93% stake. At a closing price of $154.96 per share, the value of Berkshire's remaining stake is approximately $5.446 billion.
DaVita's stock has experienced volatility, with a notable drop of over 11% on February 14. The stock has gained 42.75% in 2024 and 3.62% in 2025 so far. DaVita reported strong financial results for the fourth quarter of 2024, with revenue of $3.2947 billion, surpassing expectations of $3.266 billion. Earnings per share also exceeded forecasts, coming in at $2.24 compared to the expected $2.14.
However, DaVita's adjusted earnings forecast for 2025 is set between $10.20 and $11.30 per share, which is below the consensus estimate of $11.44 per share.
